Abivax (AAVXF) Common Equity (2021 - 2026)

Abivax has reported Common Equity for 6 years, with the latest figure at $502.9 million in Q1 2026.

• On a quarterly basis, Common Equity rose 7353.3% year-over-year to $502.9 million in Q1 2026; TTM through Mar 2026 was $502.9 million, a 7353.3% increase from a year earlier, with the FY2025 full-year figure at $529.9 million, up 1121.82% from the prior year.
• Common Equity was $502.9 million for Q1 2026 at Abivax, down from $529.9 million in the prior quarter.
• The five-year high for Common Equity was $597.7 million in Q3 2025, with the low at -$54.7 million in Q2 2025.
• Average Common Equity over 5 years is $218.5 million, with a median of $136.2 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 140.13% in 2025, then soared 7353.3% in 2026.
• Over 5 years, Common Equity stood at $7.3 million in 2022, then soared by 2775.36% to $210.9 million in 2023, then slumped by 79.44% to $43.4 million in 2024, then jumped by 1121.82% to $529.9 million in 2025, then dropped by 5.08% to $502.9 million in 2026.
• The last three Common Equity figures came in at $502.9 million (Q1 2026), $529.9 million (Q4 2025), and $597.7 million (Q3 2025), per Business Quant data.